Insights

Read our independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.

Our work is reader-supported. Sign up to our free or paid plans here.

Subcribe to Pα+
Visit the Pα+ Dashboard

The latest

Pα+ Psychedelic Bulletin #176: Drug Developers Discuss Trial Design; Massachusetts Vote is Too Close to Call as Last-Minute Donations Flow In; SEC Charges ‘Pump and Dump’ Scheme

October 11, 2024

Psychedelic Drug Developers Discuss Trial Design at Investor Event • Too Close to Call: Massachusetts Voters, Donors, to Decide Fate of State-Level Psychedelic Policy Reforms • Mushroom Mirage: SEC Charges Early Psychedelics Stock and Associates Over “Multimillion Dollar Pump-and-Dump” Scheme • and more…

Massachusetts Psychiatrists Push Back on Psychedelic Reform as Ballot Vote Looms: An Interview with Nassir Ghaemi

October 10, 2024

Next month, Massachusetts voters will decide whether to endorse Question 4, which would establish a regulated psychedelics program and enact psychedelic drug policy reforms. With polls showing a neck-and-neck race thus far, the outcome is too close to call. In this piece, Psychedelic Alpha editor Josh Hardman speaks with the President of the Massachusetts Psychiatric Society, Nassir Ghaemi, to understand why the group is opposing the initiative, as well as his broader views on psychedelics’ potential role in psychiatry.

Psychedelic Funding Update: Q3 2024

October 8, 2024

We review psychedelic company financing activity in Q3 2024, which marked a significant slow-down in investment from both Q1 and Q2. Despite this downturn, two private companies, Sunstone Therapies and Soneira Bio raised during the quarter, along with a half-dozen public companies that completed modest private placements. Here, we present updated financing charts and brief analysis.

Pα+ Psychedelic Bulletin #175: atai Sells a Third of Compass Stake; Lykos’ Unproven Psychotherapy Hampered Studies, Claim Academics; Picking Placebos

October 4, 2024

atai Sells a Third of Compass Stake to Raise Cash for In-House Programs • Lykos’ Unproven Psychotherapy Hampered Studies, Claim Authors of New Viewpoint • Picking Placebos for Psychedelic Studies • Small Study of Psilocybin in Severe TRD Among Veterans Shows Promise, But Authors Encourage Tempering Expectations • and more…

Pα+ Psychedelic Bulletin #174: Psilocybin Outperforms Escitalopram After 6 Months… or Does It? Survey Results Reveal Healthcare Practitioner Attitudes to Psychedelics; and more…

September 27, 2024

Six-Month Follow-Up Data Shows Psilocybin Outperforms Escitalopram… or Does It? • Survey Reveals Healthcare Practitioner Attitudes to Psychedelics • MIND Foundation Plots 700-Patient Psilocybin Study • Beckley Psytech-affiliated Study of Low-Dose Psilocybin for Headache Disorder Terminated Due to Recruitment Difficulties • and more…

Load more

The Library

Through our years of reporting we have covered many of the topics we believe to be important to the present and future of the psychedelics space, broadly defined. However, much of this commentary is scattered across Bulletins, deep dives, special reports and year-end reviews.

The Library provides digestible explainers on salient topics across psychedelic drug development, policy and business: from basic explainers such as “what is psychedelic-assisted therapy?” through to more complex matters such as REMS programs and bifurcated scheduling.

It’s exclusively available to our Pα+ subscribers, with new content added regularly.

Subcribe to Pα+

Pα+ Library: Bifurcated Scheduling

December 6, 2023

Pα+ Library: we introduce some of the key concepts in the matter of bifurcated scheduling; a process by which an approved drug product may be placed in a different schedule to the substance itself. As we discuss in this piece, this could have significant repercussions for psychedelic research, legality, and even taxes.

Pα+ Library: Psychedelic REMS

November 15, 2023

Pα+ Library: we sketch out what a psychedelic REMS might look like, highlighting how these programs could have an outsized impact on the post-approval delivery and accessibility of these treatments.

The Psychedelic News Feed Archives

Archived versions of our Psychedelic News Feed.

Load more